Literature DB >> 17593667

Harnessing NKT cells for therapeutic applications.

V Cerundolo1, M Salio.   

Abstract

Activation of NKT cells leads to the maturation of dendritic cells and efficiently assists priming of antigen-specific immune responses. The lack of polymorphism of CDld molecules and the evolutionary conservation of NKT cell responses highlight the important role of these cells in bridging innate and adaptive immune responses and advocate the value of harnessing this system in clinical settings. Compounds capable of fine tuning NKT cell activation should be actively exploited as potent adjuvants in vaccination strategies or as immunomodulators of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593667     DOI: 10.1007/978-3-540-69511-0_13

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  13 in total

1.  Synthesis and evaluation of 3''- and 4''-deoxy and -fluoro analogs of the immunostimulatory glycolipid, KRN7000.

Authors:  Ravinder Raju; Bernard F Castillo; Stewart K Richardson; Meena Thakur; Ryan Severins; Mitchell Kronenberg; Amy R Howell
Journal:  Bioorg Med Chem Lett       Date:  2009-06-06       Impact factor: 2.823

2.  Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity.

Authors:  Divya Chennamadhavuni; Noemi Alejandra Saavedra-Avila; Leandro J Carreño; Matthew J Guberman-Pfeffer; Pooja Arora; Tang Yongqing; Rhys Pryce; Hui-Fern Koay; Dale I Godfrey; Santosh Keshipeddy; Stewart K Richardson; Srinivasan Sundararaj; Jae Ho Lo; Xiangshu Wen; José A Gascón; Weiming Yuan; Jamie Rossjohn; Jérôme Le Nours; Steven A Porcelli; Amy R Howell
Journal:  Cell Chem Biol       Date:  2018-03-22       Impact factor: 8.116

Review 3.  Invariant natural killer T cells: bridging innate and adaptive immunity.

Authors:  Luc Van Kaer; Vrajesh V Parekh; Lan Wu
Journal:  Cell Tissue Res       Date:  2010-08-24       Impact factor: 5.249

Review 4.  Presumed guilty: natural killer T cell defects and human disease.

Authors:  Stuart P Berzins; Mark J Smyth; Alan G Baxter
Journal:  Nat Rev Immunol       Date:  2011-02       Impact factor: 53.106

5.  Alpha-S-GalCer: synthesis and evaluation for iNKT cell stimulation.

Authors:  Marisa L Blauvelt; Maryam Khalili; Weonjoo Jaung; Janet Paulsen; Amy C Anderson; S Brian Wilson; Amy R Howell
Journal:  Bioorg Med Chem Lett       Date:  2008-11-01       Impact factor: 2.823

6.  Peripheral NKT cells in simian immunodeficiency virus-infected macaques.

Authors:  Caroline S Fernandez; Angela C Chan; Konstantinos Kyparissoudis; Robert De Rose; Dale I Godfrey; Stephen J Kent
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

Review 7.  Dendritic cell-based therapeutic cancer vaccines: what we have and what we need.

Authors:  Pawel Kalinski; Julie Urban; Rahul Narang; Erik Berk; Ewa Wieckowski; Ravikumar Muthuswamy
Journal:  Future Oncol       Date:  2009-04       Impact factor: 3.404

8.  Impaired SLAM-SLAM homotypic interaction between invariant NKT cells and dendritic cells affects differentiation of IL-4/IL-10-secreting NKT2 cells in nonobese diabetic mice.

Authors:  Denis V Baev; Simone Caielli; Francesca Ronchi; Margherita Coccia; Federica Facciotti; Kim E Nichols; Marika Falcone
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

9.  Synthesis and evaluation of an acyl-chain unsaturated analog of the Th2 biasing, immunostimulatory glycolipid, OCH.

Authors:  Geetha Velmourougane; Ravinder Raju; Gabriel Bricard; Jin S Im; Gurdyal S Besra; Steven A Porcelli; Amy R Howell
Journal:  Bioorg Med Chem Lett       Date:  2009-05-18       Impact factor: 2.823

Review 10.  Glycolipid activators of invariant NKT cells as vaccine adjuvants.

Authors:  Shalu Sharma Kharkwal; Pooja Arora; Steven A Porcelli
Journal:  Immunogenetics       Date:  2016-07-05       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.